Business Context and Reporting Period
Company: Outlook Therapeutics, Inc. (OTLK)
Filing Type: Form 8-K (Current Report)
Date of Report: October 16, 2023
Reporting Period: Event date October 16, 2023; Compliance deadline April 15, 2024.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on stock listing status.
Material Changes
The Company received notification from the Nasdaq Listing Qualifications Staff regarding a failure to meet the minimum bid price requirement.
- Trigger Event: The closing bid price of the Company's common stock was below $1.00 per share for 32 consecutive business days.
- Regulation: Violation of Nasdaq Listing Rule 5550(a)(2).
- Immediate Effect: No immediate effect on the listing of the common stock on the Nasdaq Capital Market.
Outlook, Risks, and Contingencies
Compliance Timeline: The Company has 180 calendar days (until April 15, 2024) to regain compliance.
Compliance Requirement: The closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days prior to the Compliance Date.
Contingencies and Risks:
- Second Compliance Period: If the Company fails to comply by April 15, 2024, it may be eligible for an additional 180-day period if it meets other listing standards (e.g., market value of publicly held shares) and notifies Nasdaq of its intent to cure, potentially via a reverse stock split.
- Delisting Risk: If the Company fails to regain compliance and is not eligible for an extension, or if Nasdaq determines the deficiency cannot be cured, the stock will be subject to delisting.
- Appeal Process: The Company may appeal a delisting determination to a hearings panel, though success is not assured.
Management Commentary: The Company intends to actively monitor the closing bid price and evaluate available options to resolve the deficiency.
Investor Verification Checklist
- Verify the current closing bid price of OTLK to assess proximity to the $1.00 threshold.
- Monitor the Company's stock price for ten consecutive days of trading at or above $1.00 before April 15, 2024.
- Review future filings for announcements regarding a potential reverse stock split if the initial compliance period is missed.
- Check the Company's market value of publicly held shares to determine eligibility for a second compliance period.